

DATE: 11/11/53

TO: SAC, NEW YORK (100-100000)

FROM: SAC, NEW YORK (100-100000)

SUBJECT: Use of Office Of Liaison's funds for C/S Contact

100-100000 - New York

1. In connection with 100-100000, we have been advised by the Chief, CC that C/S [redacted] would be willing to undertake an investigation of hallucinamine.

2. The source, Dr. [redacted], incumbent Professor of Psychiatry and Neurology and Chairman of the Department at [redacted] College of Medicine, is well qualified in pursuing this inquiry on the effect of this drug on the central nervous system.

3. Following toxicity studies on monkeys, Dr. [redacted] plans to evaluate the drug on convicts incarcerated at the [redacted] State Penitentiary located at [redacted], approximately 125 miles from [redacted]. He believes the study, which would entail the purchase of the animals and care and his transportation, could be accomplished for a maximum of \$500.00.

4. In that financial assistance for this project could be of considerable value in the study of potential psychotropic drugs, it is recommended that Dr. [redacted] be advanced \$500.00 to cover required expenses.

given the authority to spend up to

Approved:

[redacted]

11/11/53

[redacted]

[redacted]

[redacted]

367
 HAS 5359
 30 July 1956

BS

Schizophrenic Agent

Case No. [REDACTED]

Subject:

Bulbocepinine, the alkaloid of Butcher's broom (Gorealis cava) has received attention in various countries, including Russia. The most obvious effect recorded as a result of fairly large doses, was catatonia or stupor. Smaller doses and continued treatment have effected a rise in blood pressure studies dealt especially with the effects of bulbocepinine on higher divisions of the Central Nervous System and the cerebral cortex. Dr. [REDACTED] had offered to test the substance on man, but unfortunately died before he could complete his studies. Enclosed is a copy of a preliminary report from Dr. [REDACTED] and a copy of the translation of a recent Russian publication.

Requirements:

We desire to have certain psycho-chemical properties tested on man, using the bulbocepinine which we were fortunate to obtain from [REDACTED] a sample being enclosed herewith. More bulbocepinine is available, if needed.

Among the queries we should like to include the following:

- Loss of speech, if any, in man, indicated in one case by Dr. [REDACTED]
- Loss of sensitivity to pain, if any.
- Loss of memory (observed in a single case by Dr. [REDACTED]).
- Loss of will power, if any.
- Increase in toxicity in persons with a weak type Central Nervous System.
 (see Page 21, No. 6, of Russian manuscript)
- Effects on man, compared to effects on animals as recorded in conclusions.
 (see pages 20 and 21 of Russian manuscript)

January 1957

E/SI Mr. [REDACTED] (Dr. [REDACTED])

Chief, Collection Staff, .1

This requirement pertains to National Priority Objective 14C-D-2 (a) (1) A.1.1. and
 is collected in accordance with [REDACTED]

ACTION SHEET

368

External Research Project		DATE
Chief, Administration Branch		TO
Investigation and Report on Eulbocephine		
DEADLINE DATE	FOLLOW-UP DATE	

DIVISION ROUTING

TO	DATE	ACTION REQUIRED	INIT.	COMMENTS*
Ch./Admin.	11/5/50		HE	Approved in principle 5 November 1955
Executive	11/13/50	Review	ad	DAD/P. 3 & not part of...
...	13/12/50		(15)	...
...	14/12/50		14/12	...
AD/ST	14/12/50	Approval	(15)	...
Budget Officer		Reproduction		This is part of our support to
				Whitlock & ...
				Recommend it be OK'd. ...
				Recommend approval in principle, ...
				undrafted. ...

INSTRUCTIONS: Under each comment a line should be drawn across sheet and each comment numbered in accordance with the number in the "To" Column.

* If comments bear a higher classification than the attached material, the security classification of this sheet be changed.

75-3 REPLACES FORM 30-19, WHICH MAY BE USED UNTIL SUPPLY IS EXHAUSTED)

RESTRICTED

CONFIDENTIAL

SECRET

TOP SECRET

56-601